Prospective study of anti-HCV therapy with pan-genotype direct acting anti-viral agents for patients with chronic liver diseases
Not Applicable
- Conditions
- Chronic liver disease type C
- Registration Number
- JPRN-UMIN000030599
- Lead Sponsor
- Department of Hepatology, Osaka City University Graduate School of Medicine
- Brief Summary
Glecaprevir + pibrentasvir had a remarkable anti-HCV effect in GT-1 and GT-2 patients, but not in GT-3b patients. Although this therapy was reasonably safe, it is necessary to carefully consider elderly and dropout patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 423
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active malignant tumor including liver cancer 2)Decompensated hepatic cirrhosis 3)Prohibition of per oral drugs 4)Medication contraindication drugs to pan-genotype DAAs 5)Allergy to pan-genotype DAA 6)Unsuitable condition to the present study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method